Valeant Pharmaceuticals International, Inc. (VRX)-Medical Equipment-Deals and Alliances Profile

Valeant Pharmaceuticals International, Inc. (VRX)-Medical Equipment-Deals and Alliances Profile


  • Products Id :- GDME3707D
  • |
  • Pages: 143
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Valeant Pharmaceuticals International Inc (Valeant) is a specialty pharmaceutical company. It carries out the development, manufacture and marketing of a wide range of specialty, over-the-counter (OTC) and generic drugs. The company also offers medical contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices. Valeant offers products in the areas of dermatology, neurology, eye health and branded generics. It offers a diverse mix of products in various regions across the world including the US, Canada, Australasia, Latin America, and Central and Eastern Europe. The company has manufacturing facilities in Canada and the US. Valeant is headquartered in Laval, Quebec, Canada.

Valeant Pharmaceuticals International, Inc. (VRX)-Medical Equipment-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 8

Valeant Pharmaceuticals International, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 9

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 10

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 11

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 12

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deal Details 17

Asset Purchase 17

Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 17

Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 18

Venture Financing 19

AcuFocus Raises Funds Through Series F Financing 19

Private Equity 21

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 21

Water Street Healthcare Partners Acquires OraPharma 22

Partnerships 23

Namtall Enters into Licensing Agreement with Valeant Pharma 23

Bausch & Lomb Enters Into Licensing Agreement With Cirle 24

Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 25

Bausch & Lomb Enters Into Licensing Agreement With UltraVision 26

Synergetics Enters Into Licensing Agreement With Alcon Labs 27

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 28

Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 29

Valeant Pharmaceuticals International Partners With Living Proof 30

Obagi Medical Products Extends Distribution Agreement With Suneva Medical 31

Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 32

Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 33

Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 34

Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 35

Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 36

OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 37

Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 38

Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 39

Synergetics USA Enters Into Co-Development Agreement With Retinal Solutions 40

Cutera Enters Into An Agreement With Obagi Medical Products 41

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 42

Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 44

Salix Pharma Enters Into Licensing Agreement With Photocure For Lumacan 45

Equity Offering 47

Bausch & Lomb Withdraws IPO 47

Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 49

Debt Offering 50

Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 50

Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 52

Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 53

Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 55

Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 57

Valeant Pharma Completes Public Offering Of 6.875% Senior Unsecured Notes Due 2018 For US$1,000 Million 58

Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2020 For US$700 Million 59

Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$500 Million 61

Valeant Pharma Completes Private Placement Of Senior Unsecured Notes For US$400 Million 63

Asset Transactions 64

Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 64

Stryker Acquires Neuro Portfolio Assets of Synergetics 65

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 66

Medicis Pharma Plans Sale Of LipoSonix Device 67

Stryker Completes Acquisition Of Orthopedic Assets And Worldwide Rights From Mutoh And Synergetics USA 68

Acquisition 70

Bausch + Lomb to Acquire Doctor's Allergy Formula 70

Valeant Pharma Acquires Synergetics 71

Valeant Pharma to Acquire Unilens Vision 73

Synergetics Surgical Acquires Sterimedix for USD13.5 Million 74

Valeant Canada Acquires CROMA Pharma Canada 75

Valeant Pharma Completes Acquisition Of Solta Medical For US$250 Million 76

Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 78

Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 81

OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 82

Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 84

Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 85

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 87

Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 89

Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 90

Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 92

Solta Medical Acquires Medicis Technologies From Medicis Pharma 93

ATON Acquires 100% Stake In OrthoScan 94

Solta Medical Completes Acquisition Of Aesthera 95

Valeant Pharmaceuticals International, Inc.-Key Competitors 96

Key Employees 97

Locations And Subsidiaries 99

Head Office 99

Other Locations & Subsidiaries 99

Recent Developments 108

Financial Announcements 108

Nov 08, 2016: Valeant Reports Third Quarter 2016 Financial Results 108

Aug 09, 2016: Valeant Pharmaceuticals Reports Second Quarter 2016 Financial Results 112

Jun 07, 2016: Valeant Pharmaceuticals Reports First Quarter 2016 Financial Results 114

Mar 15, 2016: Valeant Pharmaceuticals Reports Preliminary Unaudited Fourth Quarter 2015 Financial Information 116

Corporate Communications 117

Oct 06, 2016: Valeant Appoints Louis W. Yu, Ph.D. As Chief Quality Officer 117

Aug 22, 2016: Valeant Pharmaceuticals Appoints Paul S. Herendeen As Executive Vice President, Finance And Chief Financial Officer 118

Aug 08, 2016: Valeant Pharmaceuticals Announces Changes To Executive Management Team 119

Jul 28, 2016: Valeant Pharmaceuticals Announces The Addition Of Sarah B. Kavanagh To Its Board Of Directors 121

Jun 15, 2016: Valeant Pharmaceuticals Appoints Thomas W. Ross, Sr. Lead Independent Director 122

May 26, 2016: Valeant Pharmaceuticals Names Sam Eldessouky Senior Vice President And Corporate Controller 123

May 03, 2016: Joseph C. Papa Assumes Role Of Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 124

Apr 29, 2016: Valeant Announces Nominees For Election To Board Of Directors 125

Apr 25, 2016: Valeant Names Joseph C. Papa To Be Chairman And Chief Executive Officer Of Valeant Pharmaceuticals 127

Mar 21, 2016: Valeant Announces CEO Succession Plan And Changes To Board Of Directors 128

Mar 09, 2016: Valeant Pharmaceuticals Announces The Addition Of Three New Independent Directors To Its Board 129

Mar 02, 2016: Valeant Pharmaceuticals Announces Management Change 131

Feb 28, 2016: Valeant Pharmaceuticals Announces Management And Business Update 132

Legal and Regulatory 133

Aug 10, 2016: Valeant Pharmaceuticals Comments On SDNY Investigation 133

Mar 09, 2016: Valeant And R&O Pharmacy End Litigation 134

Oct 26, 2015: Valeant Pharma Receives FTC Voluntary Request Letter Related To Paragon Holdings Acquisition 135

Other Significant Developments 136

Jun 17, 2016: Valeant Pharmaceuticals Announces Significant Investments In Canadian Operations 136

May 16, 2016: Valeant Pharmaceuticals Provides Update on Regulatory Matters 137

Apr 13, 2016: Valeant Pharmaceuticals Provides Update Regarding Regulatory Matters 138

Mar 21, 2016: Valeant Provides Accounting And Financial Reporting Update 139

Oct 13, 2015: Valeant Pharmaceuticals Celebrates the Manufacturing of Four Billion Bottles of Eye Care Products at Bausch + Lomb's Greenville Solutions Plant 142

Appendix 143

Methodology 143

About GlobalData 143

Contact Us 143

Disclaimer 143

List of Figures

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 1

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 1

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 1

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Market, 2010 to YTD 2016 1

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 8

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals by Type, 2010 to YTD 2016 9

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 10

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals by Market, 2010 to YTD 2016 11

List of Tables

Valeant Pharmaceuticals International, Inc., Medical Equipment, Key Facts, 2015 1

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 1

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Year, 2010 to YTD 2016 8

Valeant Pharmaceuticals International, Inc., Medical Equipment Deals By Type, 2010 to YTD 2016 9

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals By Region, 2010 to YTD 2016 10

Valeant Pharmaceuticals International, Inc., Deals By Market, 2010 to YTD 2016 11

Valeant Pharmaceuticals International, Inc., Medical Equipment, Deals Summary, 2010 to YTD 2016 12

Valeant Pharma to Acquire Rights to IBSchek in US and Canada form Commonwealth Labs 17

Valeant Pharma Acquires Medical Devices And Food Supplements Assets Of Croma-Pharma 18

AcuFocus Raises Funds Through Series F Financing 19

Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 21

Water Street Healthcare Partners Acquires OraPharma 22

Namtall Enters into Licensing Agreement with Valeant Pharma 23

Bausch & Lomb Enters Into Licensing Agreement With Cirle 24

Unilens Vision Sciences Amends Licensing Agreement With Bausch & Lomb 25

Bausch & Lomb Enters Into Licensing Agreement With UltraVision 26

Synergetics Enters Into Licensing Agreement With Alcon Labs 27

Swedish Orphan Biovitrum Enters into Distribution Agreement with PharmaSwiss 28

Synergetics USA Enters Into Agreement With Cleveland Clinic To Develop Next Generation Intraoperative Devices 29

Valeant Pharmaceuticals International Partners With Living Proof 30

Obagi Medical Products Extends Distribution Agreement With Suneva Medical 31

Bausch & Lomb Enters Into Distribution Agreement With PhysIOL For Hydrophilic Acrylic Intraocular Lenses 32

Leica Microsystems Enters Into Distribution Agreement With Bausch & Lomb 33

Obagi Medical Products Enters Into Distribution Agreement With Suneva Medical For ReGenica Facial Rejuvenation Complex 34

Bausch & Lomb Enters Into Agreement With Cirle For Medical Technologies 35

Sinclair IS Pharma Enters Into Distribution Agreement With Valeant Pharma For Injectable Dermal Fillers 36

OrthoScan Enters Into Distribution Agreement With Ziehm Imaging 37

Unilens Vision Enters Into Distribution Agreement With No. 7 Contact Lens Lab 38

Bausch & Lomb Enters Into Distribution Agreement With Technolas Perfect Vision 39

Synergetics USA Enters Into Co-Development Agreement With Retinal Solutions 40

Cutera Enters Into An Agreement With Obagi Medical Products 41

Valeant Pharma Enters into Licensing Agreement with EyeGate Pharma 42

Bausch & Lomb Enters Into Licensing Agreement With Paragon BioTeck For Phenylephrine 44

Salix Pharma Enters Into Licensing Agreement With Photocure For Lumacan 45

Bausch & Lomb Withdraws IPO 47

Synergetics USA Files Registration Statement For Public Offering To Raise Up To US$50 Million 49

Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$1.75 Billion 50

Valeant Pharma Completes Private Placement Of Notes Due 2020 For US$500 Million 52

Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2016 For US$950 Million 53

Valeant Pharma International Completes Private Placement Of Senior Unsecured Notes Due 2022 For US$550 Million 55

Valeant Pharma Completes Private Placement Of 6.75% Senior Unsecured Notes Due 2021 For US$650 Million 57

Valeant Pharma Completes Public Offering Of 6.875% Senior Unsecured Notes Due 2018 For US$1,000 Million 58

Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2020 For US$700 Million 59

Valeant Pharma Completes Public Offering Of Senior Unsecured Notes Due 2017 For US$500 Million 61

Valeant Pharma Completes Private Placement Of Senior Unsecured Notes For US$400 Million 63

Valeant Pharma May Sell its Eye-Surgery Equipment Business for up to USD2.5 Billion 64

Stryker Acquires Neuro Portfolio Assets of Synergetics 65

Galderma Completes Acquisition of Aesthetic Dermatology Assets from Valeant Pharma for USD1.4 Billion 66

Medicis Pharma Plans Sale Of LipoSonix Device 67

Stryker Completes Acquisition Of Orthopedic Assets And Worldwide Rights From Mutoh And Synergetics USA 68

Bausch + Lomb to Acquire Doctor's Allergy Formula 70

Valeant Pharma Acquires Synergetics 71

Valeant Pharma to Acquire Unilens Vision 73

Synergetics Surgical Acquires Sterimedix for USD13.5 Million 74

Valeant Canada Acquires CROMA Pharma Canada 75

4 76

Valeant Pharma Completes Acquisition Of Bausch & Lomb For US$ 8.7 Billion 78

Synergetics USA Acquires M.I.S.S. Ophthalmics For US$3 Million 81

OlainFarm Acquires Additional 23.37% Stake In Silvanols, Pharma Products Manufacturer 82

Valeant Pharma Acquires Croma-Pharma Polska And Croma Romania From Croma-Pharma 84

Bausch & Lomb Completes Acquisition Of Remaining Stake In Technolas Perfect Vision From 20/10 Perfect Vision For US$631 Million 85

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 87

Jelfa Acquires Emo-Farm From ICN Polfa Rzeszow For US$10 Million 89

Valeant Pharma Completes Acquisition Of Orapharma From Water Street Healthcare Partners For US$442 Million 90

Bausch & Lomb Acquires Laboratorio Pfortner Cornealent SACIF 92

Solta Medical Acquires Medicis Technologies From Medicis Pharma 93

ATON Acquires 100% Stake In OrthoScan 94

Solta Medical Completes Acquisition Of Aesthera 95

Valeant Pharmaceuticals International, Inc., Key Competitors 96

Valeant Pharmaceuticals International, Inc., Key Employees 97

Valeant Pharmaceuticals International, Inc., Other Locations 99

Valeant Pharmaceuticals International, Inc., Subsidiaries 99

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Valeant Pharmaceuticals International, Inc., Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com